Citigroup
ZVRA icon

Citigroup’s Zevra Therapeutics ZVRA Stock Holding History

Citigroup’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$644K Buy
44,923
+22,993
+105% +$256K ﹤0.01% 3763
2026
Q1 		$204K Sell
21,930
-96,764
-82% -$872K ﹤0.01% 3998
2025
Q4 		$1.06M Buy
118,694
+101,172
+577% +$957K ﹤0.01% 3104
2025
Q3 		$167K Sell
17,522
-42,612
-71% -$427K ﹤0.01% 4064
2025
Q2 		$530K Buy
60,134
+16,013
+36% +$130K ﹤0.01% 3587
2025
Q1 		$330K Sell
44,121
-7,163
-14% -$56.9K ﹤0.01% 3897
2024
Q4 		$428K Buy
51,284
+20,753
+68% +$177K ﹤0.01% 3941
2024
Q3 		$212K Buy
30,531
+21,199
+227% +$144K ﹤0.01% 4298
2024
Q2 		$45.7K Buy
9,332
+2,279
+32% +$10.8K ﹤0.01% 4632
2024
Q1 		$40.9K Buy
7,053
+1,675
+31% +$10.3K ﹤0.01% 4719
2023
Q4 		$35.2K Buy
5,378
+5,360
+29,778% +$25.1K ﹤0.01% 4702
2023
Q3 		$87 Sell
18
-10,314
-100% -$51.5K ﹤0.01% 5440
2023
Q2 		$52.7K Sell
10,332
-48,164
-82% -$260K ﹤0.01% 4611
2023
Q1 		$322K Sell
58,496
-13,250
-18% -$70.1K ﹤0.01% 3451
2022
Q4 		$329K Buy
71,746
+67,717
+1,681% +$344K ﹤0.01% 3445
2022
Q3 		$25K Buy
4,029
+3,186
+378% +$18K ﹤0.01% 4662
2022
Q2 		$4K Sell
843
-1,293
-61% -$5.89K ﹤0.01% 5725
2022
Q1 		$11K Sell
2,136
-6,699
-76% -$42.6K ﹤0.01% 5492
2021
Q4 		$77K Buy
8,835
+5,578
+171% +$49.8K ﹤0.01% 4865
2021
Q3 		$30K Buy
3,257
+1,897
+139% +$19.1K ﹤0.01% 5036
2021
Q2 		$17K Buy
+1,360
New +$14.6K ﹤0.01% 5404
2016
Q4 		– Sell
-148
Closed -$11K – 7353
2016
Q3 		$11K Buy
148
+39
+36% +$2.77K ﹤0.01% 6507
2016
Q2 		$7K Sell
109
-5
-4% -$823 ﹤0.01% 6690
2016
Q1 		$26K Sell
114
-13
-10% -$3.15K ﹤0.01% 6439
2015
Q4 		$40K Buy
+127
New +$34.5K ﹤0.01% 6095

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup's ZVRA Position: Q2 2026 in Review

Citigroup increased its Zevra Therapeutics (ZVRA) stake by 105% in Q2 2026, buying an estimated $256K and bringing the position to 44,923 shares worth $644K. The position accounts for ﹤0.01% of the portfolio, ranked #3763.

Citigroup first reported a position in ZVRA in Q4 2015 and has held it in 25 quarters since. The position peaked at $1.06M in Q4 2025. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Citigroup held 44,923 shares of Zevra Therapeutics worth $644K as of Q2 2026.
  • Citigroup bought 22,993 Zevra Therapeutics shares in Q2 2026, an estimated $256K.
  • Zevra Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3763 holding.
  • Citigroup first reported a position in Zevra Therapeutics in Q4 2015 and has held it in 25 quarters since.
  • Citigroup's Zevra Therapeutics position peaked at $1.06M in Q4 2025.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.